Sentences with phrase «immune response to tumor antigens»

In this study, we examined the effectiveness of a vaccination targeting tumors that produced IL - 15 and its cell surface receptor called IL - 15R - alpha -LRB--RRB- and examined their ability to up - regulate (or increase) immune responses to tumor antigens,» Morris says.

Dr. Gnjatic's research focuses on human antigen - specific immune responses to tumor antigens, in an attempt to define new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.

Not exact matches

The central idea is to encode an antigen as RNA and inject that into the skin of the patient, whose own cells then produce the protein that triggers an immune response, either to kill tumor cells or to prevent an infection.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

He also studies the mechanisms of antigen presentation to T cells, the impact of immunoregulation on tumor antigen - specific responses, and characterization of the tumor - immune microenvironment.

The light - sensitive cells and nanoparticles, called opto - CRAC, were then delivered with the tumor antigen surrogate ovalbumin to mice with melanoma tumors in their lymph nodes to see if an immune response could be activated to target cancer cells.

Mechanistic studies showed that IFN increases antitumor immune responses by enhancing antigen presentation to T cells by dendritic cells present in the tumor microenvironment.

To trigger a vigorous immune response, antigen - presenting cells (APCs) put on display chopped - up peptides from pathogens or tumor cells.

However, despite this success, the use of immunotherapy remains limited by the scarcity of tumor - specific antigens — substances that can trigger an immune system response to a particular type of cancer.

Immunity is key to long - term responses Knowing that the immune system is capable of recognizing distinctive features of cancer cells and launching a T cell attack against those tumor antigens, and that checkpoint blockade removes a roadblock to that attack, it's logical that these drugs should work against many tumor types.

Hu14.18 K332A is a laboratory - produced antibody designed to activate the immune response against tumor cells by recognizing and binding to an antigen found on the surface of most neuroblastoma tumor cells.

Using transplantable tumor models expressing antigen in an inducible manner or spontaneous tumor models expressing nominal antigens, we try to decipher whether the tumor is ignored or leads to deletion, anergy or class switch of the specific immune response or generate suppressor T cells.

Cancer vaccines are designed to stimulate an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

While much recent research has not been published in this area, there is actually a long history of studies that show: (1) there is a significant number of antigens shared between tumors and embryonic tissues (called «oncofetal antigens») and, consequently, antibodies made against tumors can also recognize embryonic tissues, and vice versa; (2) pregnancy confers some immunity against cancer (accompanied by antibody production against oncofetal antigens), not only against its occurrence but also against its growth; (3) similar to pregnancy, an immune response against cancer can be generated by vaccinating animals with embryonic tissues.

Stimulation of the STING pathway appears essential to generate a de novo immune response comprising tumor cell death, generation of antigens, and activation of the innate and adaptive immune system.

Therapeutic vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Therapeutic cancer vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

Cancer vaccines are designed to elicit an immune response against tumor - specific or tumor - associated antigens.

There, they will be exposed to tumor antigens released from dying glioma cells through TK + valacyclovir - induced glioma cell death, and thus mediate a specific anti-malignant glioma immune response against remaining malignant glioma cells.

Low - dose chemotherapy, radiation, or targeted therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.

They do, however, play a key role in helping to boost the anti-tumor immune response by: (1) expanding the number and improving the function of existing CTLs that are specific to the same tumor antigen; and (2) providing help to other immune cells, including B lymphocytes that are precursors to antibodies and natural killer (NK) cells that are also important in the overall anti-tumor immune response.

In the experiments described in the paper, the MGH team confirmed that their mesothelin - targeting fusion protein binds to mesothelin on either ovarian cancer or mesothelioma cells, activates dendritic cells, and enhances the cells» processing and presentation of several different tumor antigens, inducing a number of T - cell - based immune responses.

«We have created a potentially much less expensive approach to making a therapeutic cancer vaccine that, while targeting a single tumor antigen, generates an immune response against multiple antigens.

About G100: G100 is Immune Design's first product candidate solely generated from the GLAAS ® platform and is designed to leverage the range of endogenous antigens (including neoantigens) found in the tumor microenvironment to create a systemic anti-tumor immune response from local injection.